Fiduciary Alliance LLC Boosts Position in Novo Nordisk A/S (NYSE:NVO)

Fiduciary Alliance LLC boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 11.4% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,107 shares of the company’s stock after purchasing an additional 829 shares during the quarter. Fiduciary Alliance LLC’s holdings in Novo Nordisk A/S were worth $697,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Strategic Investment Solutions Inc. IL purchased a new position in Novo Nordisk A/S during the 2nd quarter worth approximately $25,000. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $28,000. Abound Wealth Management raised its position in Novo Nordisk A/S by 257.4% in the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after purchasing an additional 157 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in Novo Nordisk A/S during the 3rd quarter worth $42,000. Finally, Carolina Wealth Advisors LLC purchased a new position in Novo Nordisk A/S during the 3rd quarter worth $48,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on NVO. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group raised Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus target price of $140.20.

Novo Nordisk A/S Stock Down 2.1 %

Novo Nordisk A/S stock opened at $84.43 on Tuesday. The stock’s 50 day moving average price is $99.84 and its 200 day moving average price is $118.61. Novo Nordisk A/S has a 1-year low of $81.50 and a 1-year high of $148.15. The company has a market cap of $378.88 billion, a PE ratio of 27.32, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.